News
There's more to work than life.
Phase 1 clinical trial of its investigational half-life extended anti-IL-23 monoclonal antibody, SPY003. This milestone marks our fourth on-time clinical trial initiation in nine months.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback